Publication

Article

Oncology & Biotech News
December 2010
Volume 4
Issue 12

FDA Approves Zactima

Author(s):

An FDA advisory panel voted 10 to 0 in favor of approving Zactima (vandetanib) for patients with medullary thyroid cancer who have symptomatic, progressive disease.

An FDA advisory panel voted 10 to 0 in favor of approving Zactima (vandetanib) for patients with medullary thyroid cancer who have symptomatic, progressive disease. The panel expressed concerns about “substantial” drug-related toxicity associated with the 300-mg daily dose. Members said that patients taking Zactima appeared to be at greater risk for stroke and other cerebrovascular events and a prolonged QT interval.

Related Videos
Yungan Tao, MD
Jared Weiss, MD
Lillian L. Siu, MD, FRCPC
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma